329PAbemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET). (23rd October 2018) - Grischke, E-M; Neven, P; Lin, Y; Kaufman, P A; Sledge, G W